SHANGHAI RENDU BIOTECHNOLOGY CO.(SH:688193) Xin Lang Cai Jing·2025-10-31 02:17Core Insights - RenDu Bio (688193.SH) reported its Q3 2025 results on October 31, 2025, highlighting a total of 6 institutional investors holding shares, amounting to 13.6487 million shares, which represents 34.06% of the total share capital [1] Institutional Holdings - The total institutional holding percentage decreased by 3.26 percentage points compared to the previous quarter [1] - The institutional investors include MING LI INVESTMENTS LIMITED, Changzhou Jin Xin Venture Capital Co., Ltd., CENTRAL CHIEF LIMITED, Runcong (Shanghai) Enterprise Management Center (Limited Partnership), Nanjing Gaoke Xinjun Growth Phase I Equity Investment Partnership (Limited Partnership), and CICC-Pudong Development Bank-CICC Fengzhong No. 41 Employee Participation in Sci-Tech Innovation Board Strategic Allocation Collective Asset Management Plan [1] Public Fund Activity - A total of 31 public funds were disclosed this period, including Huaxia Pantai Mixed (LOF) A, Huaxia New Jinxiu Mixed A, GF Multi-Factor Mixed, Huashang Quantitative Quality Selected Mixed, and E Fund Shanghai Stock Exchange Sci-Tech Innovation Board Comprehensive ETF [1] Foreign Investment Trends - One foreign fund, CENTRAL CHIEF LIMITED, reduced its holdings by 1.00% compared to the previous quarter [1]